KALA BIO Q1 net loss $8.9M; cash $42.2M; KPI-012 Phase 2b topline data due Q3 2025

KALA BIO, Inc.

2025-Q1 EPS reported -$1.41 vs consensus -$103.53 ▲ beat (+98.6%)

Cash and cash equivalents of $42.2M as of March 31, 2025, expected to fund operations into Q1 2026.
Q1 2025 net loss $8.9M ($1.41 per diluted share) vs $11.8M ($4.20) prior year; operating loss $10.7M.
G&A $4.6M (down from $5.4M); R&D $6.1M (down from $6.4M). Weighted shares 6.3M vs 2.8M.
Phase 2b CHASE trial of KPI-012 in PCED continues enrolling; topline data anticipated in Q3 2025.
Exploring KPI-012 for Limbal Stem Cell Deficiency; preclinical KPI-014 for inherited retinal diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.